TY - JOUR
T1 - Dynamic diffuse optical tomography for monitoring neoadjuvant chemotherapy in patients with breast cancer
AU - Gunther, Jacqueline E.
AU - Lim, Emerson A.
AU - Kim, Hyun K.
AU - Flexman, Molly
AU - Altoé, Mirella
AU - Campbell, Jessica A.
AU - Hibshoosh, Hanina
AU - Crew, Katherine D.
AU - Kalinsky, Kevin
AU - Hershman, Dawn L.
AU - Hielscher, Andreas H.
N1 - Funding Information:
J.E.G. was supported in part by an Integrative Graduate Education and Research Traineeship from the National Science Foundation and a TL1 grant by the National Institutes of Health. E.A.L. was supported by the Susan G. Komen for the Cure Post-Doctoral Clinical Research Fellowship Grant (KG 111293). Supported in part by the Witten Family Fund, Breast Cancer Research Foundation, and National Institutes of Health (grant 11223309). M.F. was supported by a PhD scholarship from the Natural Sciences and Engineering Research Council of Canada. In addition, K.K. was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant KL2 TR000081. The content is solely responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© RSNA, 2018.
PY - 2018/6
Y1 - 2018/6
N2 - Purpose: To identify dynamic optical imaging features that associate with the degree of pathologic response in patients with breast cancer during neoadjuvant chemotherapy (NAC). Materials and Of 40 patients with breast cancer who participated in a Methods: longitudinal study between June 2011 and March 2016, 34 completed the study. There were 13 patients who obtained a pathologic complete response (pCR) and 21 patients who did not obtain a pCR. Imaging data from six subjects were excluded from the study because either the patients dropped out of the study before it was finished or there was an instrumentation malfunction. Two weeks into the treatment regimen, three-dimensional images of both breasts during a breath hold were acquired by using dynamic diffuse optical tomography. Features from the breath-hold traces were used to distinguish between response groups. Receiver operating characteristic (ROC) curves and sensitivity analysis were used to determine the degree of association with 5-month treatment outcome. Results: An ROC curve analysis showed that this method could identify patients with a pCR with a positive predictive value of 70.6% (12 of 17), a negative predictive value of 94.1% (16 of 17), a sensitivity of 92.3% (12 of 13), a specificity of 76.2% (16 of 21), and an area under the ROC curve of 0.85. Conclusion: Several dynamic optical imaging features obtained within 2 weeks of NAC initiation were identified that showed statistically significant differences between patients with pCR and patients without pCR as determined 5 months after treatment initiation. If confirmed in a larger cohort prospective study, these dynamic imaging features may be used to predict treatment outcome as early as 2 weeks after treatment initiation.
AB - Purpose: To identify dynamic optical imaging features that associate with the degree of pathologic response in patients with breast cancer during neoadjuvant chemotherapy (NAC). Materials and Of 40 patients with breast cancer who participated in a Methods: longitudinal study between June 2011 and March 2016, 34 completed the study. There were 13 patients who obtained a pathologic complete response (pCR) and 21 patients who did not obtain a pCR. Imaging data from six subjects were excluded from the study because either the patients dropped out of the study before it was finished or there was an instrumentation malfunction. Two weeks into the treatment regimen, three-dimensional images of both breasts during a breath hold were acquired by using dynamic diffuse optical tomography. Features from the breath-hold traces were used to distinguish between response groups. Receiver operating characteristic (ROC) curves and sensitivity analysis were used to determine the degree of association with 5-month treatment outcome. Results: An ROC curve analysis showed that this method could identify patients with a pCR with a positive predictive value of 70.6% (12 of 17), a negative predictive value of 94.1% (16 of 17), a sensitivity of 92.3% (12 of 13), a specificity of 76.2% (16 of 21), and an area under the ROC curve of 0.85. Conclusion: Several dynamic optical imaging features obtained within 2 weeks of NAC initiation were identified that showed statistically significant differences between patients with pCR and patients without pCR as determined 5 months after treatment initiation. If confirmed in a larger cohort prospective study, these dynamic imaging features may be used to predict treatment outcome as early as 2 weeks after treatment initiation.
KW - Adult
KW - Breast/diagnostic imaging
KW - Breast Neoplasms/diagnostic imaging
KW - Chemotherapy, Adjuvant
KW - Female
KW - Humans
KW - Longitudinal Studies
KW - Middle Aged
KW - Neoadjuvant Therapy/methods
KW - Sensitivity and Specificity
KW - Tomography, Optical/methods
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85046683789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046683789&partnerID=8YFLogxK
U2 - 10.1148/radiol.2018161041
DO - 10.1148/radiol.2018161041
M3 - Article
C2 - 29431574
AN - SCOPUS:85046683789
SN - 0033-8419
VL - 287
SP - 778
EP - 786
JO - Radiology
JF - Radiology
IS - 3
ER -